First CAR T-cell therapy for multiple myeloma: AbecmaMarch 29, 2021Multiple MyelomaLymphoma & Plasma Cell Disorders
Poor survival with COVID in patients who have had HSCTMarch 26, 2021Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
FDA scrutinizes cancer therapies granted accelerated approvalMarch 18, 2021Breast CancerGenitourinary CancerLung CancerLymphoma & Plasma Cell DisordersMultiple MyelomaOncologyHematology
High-dose chemo no better than standard dose for B-cell lymphomaMarch 17, 2021Lymphoma & Plasma Cell DisordersHematologyOncology
Don’t delay: Cancer patients need both doses of COVID vaccineMarch 15, 2021Multiple MyelomaAMLBreast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung Cancer
‘Phenomenal’ results with CAR T cells in R/R multiple myelomaMarch 4, 2021Multiple MyelomaLymphoma & Plasma Cell DisordersHematologyOncology
CAR T-cell products shine in real-world setting, reveal new insightsFebruary 18, 2021Lymphoma & Plasma Cell DisordersOncologyHematology
How has the pandemic affected rural and urban cancer patients?February 18, 2021Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell DisordersMelanoma
FDA okays new CAR T-cell treatment for large B-cell lymphomasFebruary 8, 2021Lymphoma & Plasma Cell DisordersHematology
COVID-19 vaccination in cancer patients: NCCN outlines prioritiesFebruary 1, 2021Breast CancerGenitourinary CancerHead & Neck/Thyroid CancersLeukemia, Myelodysplasia, TransplantationLung CancerLymphoma & Plasma Cell DisordersMelanoma
Model predicts acute kidney injury in cancer patients a month in advanceFebruary 1, 2021Genitourinary CancerLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersLung CancerBreast Cancer
Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplantDecember 18, 2020Multiple MyelomaLymphoma & Plasma Cell DisordersHematologyOncology
Study found dual-targeted CAR T highly active against relapsed/refractory multiple myelomaDecember 15, 2020Multiple MyelomaLymphoma & Plasma Cell DisordersOncology
Extended virus shedding after COVID-19 in some patients with cancerDecember 10, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple Myeloma
Durable responses with anti-BCMA CAR T-cell for multiple myelomaDecember 6, 2020Multiple MyelomaLymphoma & Plasma Cell DisordersHematologyOncology
